FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Norbert Gattermann

Research Profile

Disorders

Concepts & Ideas

Procedures

Blood Transfusions

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Anna Maassen; Kathrin Nachtkamp; Corinna Strupp; Carlo Aul; Norbert Gattermann; Aristoteles Giagounidis; Rainer Haas; Barbara Hildebrandt; Andrea Kuendgen; Ulrich Germing
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.
F Nolte; U Platzbecker; C Schumann; M Taupitz; M Baier; Norbert Gattermann; A Giagounidis; D Haase; B Höchsmann; W K Hofmann; A Junkes; Oliver Leismann; M Lübbert; A Lück; H Schrezenmeier
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Vip Viprakasit; Gabor Domokos; Norbert Gattermann; Dany Habr; Jong Wook Lee; Nicolas Martin; John B Porter; Ali T Taher; Maria Domenica Cappellini
Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Norbert Gattermann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Anna Maassen; Kathrin Nachtkamp; Corinna Strupp; Carlo Aul; Norbert Gattermann; Aristoteles Giagounidis; Rainer Haas; Barbara Hildebrandt; Andrea Kuendgen; Ulrich Germing
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.
Leukemia research 2013;37(1):64-70.
2013: F Nolte; U Platzbecker; C Schumann; M Taupitz; M Baier; Norbert Gattermann; A Giagounidis; D Haase; B Höchsmann; W K Hofmann; A Junkes; Oliver Leismann; M Lübbert; A Lück; H Schrezenmeier
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Annals of hematology 2013;92(2):191-8.
2013: Vip Viprakasit; Gabor Domokos; Norbert Gattermann; Dany Habr; Jong Wook Lee; Nicolas Martin; John B Porter; Ali T Taher; Maria Domenica Cappellini
Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.
Blood transfusion = Trasfusione del sangue 2013;11(1):108-22.
2012: Norbert Gattermann
SF3B1 and the riddle of the ring sideroblast.
Blood 2012;120(16):3167-8.
2012: Norbert Gattermann; Agnes Guerci-Bresler; Dany Habr; Andrea Marcellari; Bernard Roubert; Mathias Schmid; Michael Stadler; Kerry Taylor; Dominique Vassilieff; Matteo Della Porta; Pierre Fenaux; Carlo Finelli; Christian Rose
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Haematologica 2012;97(9):1364-71.
2012: Judith Neukirchen; Corinna Strupp; Frank Fox; Ulrich Germing; Rainer Haas; Andrea Kündgen; Kathrin Nachtkamp; Norbert Gattermann
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
Leukemia research 2012;36(8):1067-70.
2012: Ulrich Germing; Aristoteles Giagounidis; Rainer Haas; Carsten Starke; Corinna Strupp; Norbert Gattermann; Carlo Aul
Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes.
Leukemia research 2012;36(6):727-34.
2012: Norbert Gattermann; Klaus Blumenstengel; Mariele Goebeler; Matthias Groschek; Andrea Jarisch; Alexia Junkes; Oliver Leismann; Christoph Losem; Maria Procaccianti; Rudolf Schlag; Ulrich Germing
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
European journal of haematology 2012;88(3):260-8.
2012: Ulrich Germing; Rainer Haas; Andrea Kündgen; Norbert Gattermann
[Myelodysplastic syndromes (MDS)].
Deutsche medizinische Wochenschrift (1946) 2012;137(5):183-5.
2012: Thomas Schroeder; Michael Stadler; Fabian Zohren; Friederike Braulke; Ingmar Bruns; Akos G Czibere; Roland Fenk; Norbert Gattermann; Rainer Haas; Detlef Haase; Sabine Kayser; Viola Klärner; Guido Kobbe; Nicolaus Kröger; Andrea Kuendgen; Uwe Platzbecker; Richard F Schlenk; Ulrich Germing
Therapy-related myeloid neoplasms following treatment with radioiodine.
Haematologica 2012;97(2):206-12.
2012: Enrico Monaca; Norbert Gattermann; Tobias Jüttner; Michael Winterhalter
Anaesthesia in a patient with subarachanoidal haemorrhage and high oxygen affinity haemoglobinopathy (HB york): case report.
BMC anesthesiology 2012;12():19.
2012: Norbert Gattermann; Lenka Kellermann; Andrea Kündgen; Bernadette Paessens; Matti Zeffel; Ulrich Germing
Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysis.
Onkologie 2012;35(6):350-6.
2012: Norbert Gattermann
Pathophysiological and clinical aspects of iron chelation therapy in MDS.
Current pharmaceutical design 2012;18(22):3222-34.
2011: Judith Neukirchen; Wilma M Schoonen; Corinna Strupp; Carlo Aul; Norbert Gattermann; Rainer Haas; Ulrich Germing
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.
Leukemia research 2011;35(12):1591-6.
2011: Andrea Kuendgen; Kathrin Nachtkamp; Judith Neukirchen; Oliver G Ottmann; Julie Schanz; Ulrich Germing; Rainer Haas; Detlef Haase; Barbara Hildebrandt; Gesine Bug; Ariane Dienst; Norbert Gattermann
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.
Clinical epigenetics 2011;2(2):389-99.
2011: Verena Schildgen; Ramona-Liza Tillmann; Michael Wulfert; Norbert Gattermann; Jessica Lüsebrink; Oliver Schildgen
Human bocavirus is not detectable in bone marrow from patients with myelodysplastic syndromes.
Influenza and other respiratory viruses 2011;5(4):221-2.
2011: Lewis R Silverman; Pierre Fenaux; Norbert Gattermann; Steven D Gore; Eva Hellström-Lindberg; Alan F List; Ghulam J Mufti; Valeria Santini; Guillermo Sanz; John F Seymour
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
Cancer 2011;117(12):2697-702.
2011: Verena Schildgen; Michael Wulfert; Norbert Gattermann
Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes.
Experimental hematology 2011;39(6):666-675.e1.
2011: Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood 2011;117(4):1141-5.
2011: Norbert Gattermann; Eliezer A Rachmilewitz
Iron overload in MDS-pathophysiology, diagnosis, and complications.
Annals of hematology 2011;90(1):1-10.
2010: Alexander E Smith; Azim Mohamedali; Austin Kulasekararaj; Ziyi Lim; Joop Gäken; Nicholas C Lea; Bartlomiej Przychodzen; Syed A Mian; Erick E Nasser; Claire Shooter; Nigel B Westwood; Corinna Strupp; Norbert Gattermann; Jaroslaw P Maciejewski; Ulrich Germing; Ghulam J Mufti
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Blood 2010;116(19):3923-32.
2010: Pierre Fenaux; David Bowen; Norbert Gattermann; Eva Hellström-Lindberg; Wolf-Karsten Hofmann; Michael Pfeilstöcker; Guillermo Sanz; Valeria Santini
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
Leukemia research 2010;34(11):1410-6.
2010: T Schroeder; Leilani Ruf; A Bernhardt; Barbara Hildebrandt; Manuel Aivado; Carlo Aul; Norbert Gattermann; Rainer Haas; Ulrich Germing
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(11):2267-71.
2010: Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Arnold Ganser; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Gabor Domokos; Bernard Roubert; Christian Rose
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Leukemia research 2010;34(9):1143-50.
2010: Akira Matsuda; Ulrich Germing; Itsuro Jinnai; Kayano Araseki; Andrea Kuendgen; Corinna Strupp; Masako Iwanaga; Yasushi Miyazaki; Tomoko Hata; Masami Bessho; Norbert Gattermann; Masao Tomonaga
Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes.
Leukemia research 2010;34(8):974-80.
2010: Pierre Fenaux; Norbert Gattermann; John F Seymour; Eva Hellström-Lindberg; Ghulam J Mufti; Ulrich Duehrsen; Steven D Gore; Fernando Ramos; Odile Beyne-Rauzy; Alan List; David McKenzie; Jay Backstrom; Charles L Beach
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
British journal of haematology 2010;149(2):244-9.
2010: Maria Domenica Cappellini; John Porter; Amal El-Beshlawy; Chi kong Li; John F Seymour; Mohsen Elalfy; Norbert Gattermann; Stéphane Giraudier; Jong-Wook Lee; Lee Lee Chan; Kai-Hsin Lin; Christian Rose; Ali Taher; Swee Lay Thein; Vip Viprakasit; Dany Habr; Gabor Domokos; Bernard Roubert; Antonis Kattamis
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Haematologica 2010;95(4):557-66.
2010: Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven D Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):562-9.
2010: Norbert Gattermann
How to treat MDS without stem cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(1 Suppl):S30-6.
2009: Roland Kronenberger; Eberhard Schleyer; Martin Bornhäuser; Gerhard Ehninger; Norbert Gattermann; Sabine Blum
Imatinib in breast milk.
Annals of hematology 2009;88(12):1265-6.
2009: Judith Neukirchen; Sabine Blum; Andrea Kuendgen; Corinna Strupp; Manuel Aivado; Rainer Haas; Carlo Aul; Norbert Gattermann; Ulrich Germing
Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
European journal of haematology 2009;83(5):477-82.
2009: Isabel Möller; Sabine Blum; Norbert Gattermann; Rainer Haas; Kerstin Habersang; Ulrich Germing; Andrea Kuendgen
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Annals of hematology 2009;88(11):1141-4.
2009: Azim Mohamedali; Alexander E Smith; Joop Gaken; Nicholas C Lea; Syed A Mian; Nigel B Westwood; Corinna Strupp; Norbert Gattermann; Ulrich Germing; Ghulam J Mufti
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(24):4002-6.
2009: Kathrin Nachtkamp; Andrea Kündgen; Corinna Strupp; Aristoteles Giagounidis; Guido Kobbe; Norbert Gattermann; Rainer Haas; Ulrich Germing
Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Leukemia research 2009;33(8):1024-8.
2009: Norbert Gattermann
The treatment of secondary hemochromatosis.
Deutsches Ärzteblatt international 2009;106(30):499-504, I.
2009: Peter Valent; Wolf-Karsten Hofmann; Guntram Büsche; Karl Sotlar; Hans-Peter Horny; Detlef Haase; Torsten Haferlach; Wolfgang Kern; Peter Bettelheim; Christian Baumgartner; Wolfgang R Sperr; Thomas Nösslinger; Friedrich Wimazal; Aristoteles A Giagounidis; Michael Lübbert; Otto Krieger; Hans-Jochem Kolb; Reinhard Stauder; Michael Pfeilstöcker; Norbert Gattermann; Christa Fonatsch; Carlo Aul; Ulrich Germing
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.
Annals of hematology 2009;88(7):607-11.
2009: Thomas Schroeder; Akos Czibere; Fabian Zohren; Manuel Aivado; Norbert Gattermann; Ulrich Germing; Rainer Haas
Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic syndromes with the highest expression in refractory anemia with excess of blasts and secondary acute myeloid leukemia.
Leukemia & lymphoma 2009;50(6):1043-6.
2009: Esther Zipperer; Daniela Pelz; Kathrin Nachtkamp; Andrea Kuendgen; Corinna Strupp; Norbert Gattermann; Rainer Haas; Ulrich Germing
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.
Haematologica 2009;94(5):729-32.
2009: Ingmar Bruns; Akos Czibere; Johannes C Fischer; F Roels; R-P Cadeddu; S Buest; D Bruennert; A N Huenerlituerkoglu; Nikolas Hendrik Stoecklein; R Singh; Luiz F Zerbini; M Jäger; Guido Kobbe; Norbert Gattermann; Ralf Kronenwett; Benedikt Brors; Rainer Haas
The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.
Leukemia 2009;23(5):892-9.
2009: D Bruennert; Akos Czibere; Ingmar Bruns; Ralf Kronenwett; Norbert Gattermann; Rainer Haas; Frank Neumann
Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.
Leukemia 2009;23(5):983-5.
2009: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; john bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
The lancet oncology 2009;10(3):223-32.
2009: Wolf C Prall; Akos Czibere; Franck Grall; Dimitrios Spentzos; Ulrich Steidl; Aristoteles Giagounidis; Andrea Kuendgen; Hasan Otu; Astrid Rong; Towia Libermann; Ulrich Germing; Norbert Gattermann; Rainer Haas; Manuel Aivado
Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.
International journal of hematology 2009;89(2):173-87.
2009: Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc Loriaux
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Blood 2009;113(8):1749-55.
2009: Frank Neumann; Norbert Gattermann; Hans-Ulrich Barthelmes; Rainer Haas; Ulrich Germing
Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
Leukemia research 2009;33(2):232-6.
2008: Frank Neumann; Judith Markett; Roland Fenk; Monika Pooten; Anne Koch; Daniela Bruennert; Nadine Schimkus; Michael Wulfert; Brigitte Royer-Pokora; Ralf Kronenwett; Rainer Haas; Norbert Gattermann
Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.
Hematological oncology 2008;26(4):213-8.
2008: Norbert Gattermann; Wolf-Karsten Hofmann; Axel Meessen; Stephan Schmitz; Anton Tsamaloukas; Tanja Vollmer; Ulrich Wedding; Carlotta Plesnila-Frank; Wolfgang Schramm; Karin Berger
Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany.
Onkologie 2008;31(8-9):477-84.
2008: Norbert Gattermann
Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
International journal of hematology 2008;88(1):24-9.
2008: Li Wang; Carrie Fidler; Nandita Nadig; Aristoteles Giagounidis; Matteo Della Porta; Luca Malcovati; Sally Killick; Norbert Gattermann; Carlo Aul; Jacqueline Boultwood; james wainscoat
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
Haematologica 2008;93(7):994-1000.
2008: Christoph Sucker; Georg Mansmann; Stefan Steiner; Norbert Gattermann; Anette Schmitt-Graeff; Robert Loncar; Rüdiger E Scharf; Marcus Stockschlader
Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2008;14(3):360-4.
2008: Michael Wulfert; Anna C Küpper; Christoph Tapprich; Sylvia S Bottomley; David Bowen; Ulrich Germing; Rainer Haas; Norbert Gattermann
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
Experimental hematology 2008;36(5):577-86.
2008: Philipp le Coutre; Oliver G Ottmann; Francis Giles; Dong-Wook Kim; Jorge Cortes; Norbert Gattermann; Jane F Apperley; Richard A Larson; Elisabetta Abruzzese; Stephen G O'Brien; Kazimierz Kuliczkowski; Andreas Hochhaus; Francois-Xavier Mahon; Giuseppe Saglio; marco gobbi; Yok-Lam Kwong; Michele Baccarani; Timothy Hughes; giovanni martinelli; Jerald P Radich; Ming Zheng; Yaping Shou; Andrew Lamb
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood 2008;111(4):1834-9.
2008: John Porter; Renzo Galanello; Giuseppe Saglio; Ellis J Neufeld; Elliott Vichinsky; Maria Domenica Cappellini; Nancy F Olivieri; Antonio Piga; Melody J Cunningham; Denis Soulières; Norbert Gattermann; Gilbert Tchernia; Johan Maertens; Patricia J Giardina; Janet Kwiatkowski; Giovanni Quarta; Michael Jeng; Gian Luca Forni; Michael Stadler; Holger Cario; Louisette Debusscher; Matteo Della Porta; Mario Cazzola; Peter Greenberg; Giuliana Alimena; Bertrand Rabault; Insa Gathmann; John Malcolm Ford; Daniele Alberti; Christian Rose
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
European journal of haematology 2008;80(2):168-76.
2008: Pierre Fenaux; Norbert Gattermann; Eva Hellström-Lindberg; D McKenzie; V Santini; G Sanz; L Zimmerman; C L Beach; Steven D Gore; A F List; G J Mufti; J F Seymour; J Backstrom; L B Silverman
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update.
Ecancermedicalscience 2008;2():121.
2008: L R Silverman; Steven D Gore; A F List; G J Mufti; J F Seymour; J Backstrom; Pierre Fenaux; Norbert Gattermann; Eva Hellström-Lindberg; D McKenzie; V Santini; G Sanz; C L Beach
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.
Ecancermedicalscience 2008;2():118.
2008: Sabine Knipp; Corinna Strupp; Norbert Gattermann; Barbara Hildebrandt; Marc Schapira; Aristoteles Giagounidis; Carlo Aul; Rainer Haas; Ulrich Germing
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome.
Leukemia research 2008;32(1):33-7.
2007: Norbert Gattermann
Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Leukemia research 2007;31 Suppl 3():S10-5.
2007: Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil N Bhalla; Giuliana Alimena; Francesca Palandri; Gert Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark R Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood 2007;110(10):3540-6.
2007: Azim Mohamedali; Joop Gäken; Natalie A Twine; Wendy Ingram; Nigel B Westwood; Nicholas C Lea; Janet Hayden; Nora Donaldson; Carlo Aul; Norbert Gattermann; Aristotle Giagounidis; Ulrich Germing; Alan F List; Ghulam J Mufti
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.
Blood 2007;110(9):3365-73.
2007: Sabine Knipp; Norbert Gattermann; Marc Schapira; Herbert Käferstein; Ulrich Germing
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Leukemia research 2007;31(11):1585-7.
2007: Wolf C Prall; Akos Czibere; Marcus Jäger; Dimitrios Spentzos; Towia Libermann; Norbert Gattermann; Rainer Haas; Manuel Aivado
Age-related transcription levels of KU70, MGST1 and BIK in CD34+ hematopoietic stem and progenitor cells.
Mechanisms of ageing and development 2007;128(9):503-10.
2007: Andrea Kuendgen; Norbert Gattermann
Valproic acid for the treatment of myeloid malignancies.
Cancer 2007;110(5):943-54.
2007: Sabine Knipp; Barbara Hildebrand; Andrea Kündgen; Aristoteles Giagounidis; Guido Kobbe; Rainer Haas; Carlo Aul; Norbert Gattermann; Ulrich Germing
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
Cancer 2007;110(2):345-52.
2007: Ulrich Germing; Corinna Strupp; Sabine Knipp; Andrea Kuendgen; Aristoteles Giagounidis; Barbara Hildebrandt; Carlo Aul; Rainer Haas; Norbert Gattermann; john bennett
Chronic myelomonocytic leukemia in the light of the WHO proposals.
Haematologica 2007;92(7):974-7.
2007: Corinna Strupp; Sabine Knipp; J Hartmann; Norbert Gattermann; Rainer Haas; Ulrich Germing
A pilot study of bendamustine in elderly patients with high-risk MDS and AML.
Leukemia & lymphoma 2007;48(6):1161-6.
2007: Akira Matsuda; Ulrich Germing; Itsuro Jinnai; Masako Iwanaga; Motohiro Misumi; Andrea Kuendgen; Corinna Strupp; Y Miyazaki; Hideki Tsushima; M Sakai; Masami Bessho; Norbert Gattermann; Carlo Aul; Masao Tomonaga
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.
Leukemia 2007;21(4):678-86.
2007: Elena Diaz-Blanco; Ingmar Bruns; Frank Neumann; Johannes C Fischer; Thorsten Graef; M Rosskopf; Benedikt Brors; Sabrina Pechtel; Simone Bork; A Koch; A Baer; Ulrich-Peter Rohr; Guido Kobbe; Norbert Gattermann; Rainer Haas; A von Haeseler; Ralf Kronenwett
Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
Leukemia 2007;21(3):494-504.
2007: Andrea Kuendgen; Thorsten Graef; Fabian Zohren; Barbara Hildebrandt; Ali Hünerlitürkoglu; Norbert Gattermann; Rainer Haas; Guido Kobbe
Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.
Leukemia research 2007;31(3):407-9.
2007: Norbert Gattermann; Johan Billiet; Ralf Kronenwett; Esther Zipperer; Ulrich Germing; Friedel Nollet; Arnold Criel; Dominik Selleslag
High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
Blood 2007;109(3):1334-5.
2007: Manuel Aivado; Dimitrios Spentzos; Ulrich Germing; Gil Alterovitz; Xiao-Ying Meng; Franck Grall; Aristoteles Giagounidis; Giannoula Klement; Ulrich Steidl; Hasan H Otu; Akos Czibere; Wolf C Prall; Christof Iking-Konert; Michelle Shayne; Marco F Ramoni; Norbert Gattermann; Rainer Haas; Constantine S Mitsiades; Eric T Fung; Towia Libermann
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(4):1307-12.
2006: Ulrich Germing; Corinna Strupp; Andrea Kuendgen; Shadi Isa; Sabine Knipp; Barbara Hildebrandt; Aristoteles Giagounidis; Carlo Aul; Norbert Gattermann; Rainer Haas
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Haematologica 2006;91(12):1596-604.
2006: Andrea Kuendgen; Corinna Strupp; Manuel Aivado; Barbara Hildebrandt; Rainer Haas; Norbert Gattermann; Ulrich Germing
Myelodysplastic syndromes in patients younger than age 50.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(34):5358-65.
2006: M M Ceesay; Nicholas C Lea; Wendy Ingram; Nigel B Westwood; Joop Gäken; Azim Mohamedali; J Cervera; Ulrich Germing; Norbert Gattermann; Aristotle Giagounidis; Z Garcia-Casado; G Sanz; Ghulam J Mufti
The JAK2 V617F mutation is rare in RARS but common in RARS-T.
Leukemia 2006;20(11):2060-1.
2006: Manuel Aivado; Norbert Gattermann; Astrid Rong; Aristoteles Giagounidis; Wolf C Prall; Akos Czibere; Barbara Hildebrandt; Rainer Haas; Sylvia S Bottomley
X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.
Blood cells, molecules & diseases 2006;37(1):40-5.
2006: Wendy Ingram; Nicholas C Lea; J Cervera; Ulrich Germing; Pierre Fenaux; Bruno Cassinat; Jean-Jacques Kiladjian; Judit Várkonyi; P Antunovic; Nigel B Westwood; Matthew Arno; Azim Mohamedali; J Gaken; T Kontou; Barbara Czepulkowski; N A Twine; J Tamaska; J Csomer; S Benedek; Norbert Gattermann; E Zipperer; Aristotle Giagounidis; Z Garcia-Casado; G Sanz; Ghulam J Mufti
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.
Leukemia 2006;20(7):1319-21.
2006: Michael Wulfert; Christoph Tapprich; Norbert Gattermann
Optimized PCR fragments for heteroduplex analysis of the whole human mitochondrial genome with denaturing HPLC.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;831(1-2):236-47.
2006: Ulrich Germing; Corinna Strupp; Andrea Kuendgen; Manuel Aivado; Aristoteles Giagounidis; Barbara Hildebrandt; Carlo Aul; Rainer Haas; Norbert Gattermann
Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.
British journal of haematology 2006;132(2):162-7.
2006: Andrea Kuendgen; Mathias Schmid; Richard F Schlenk; Sabine Knipp; Barbara Hildebrandt; Christian Steidl; Ulrich Germing; Rainer Haas; Hartmut Dohner; Norbert Gattermann
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Cancer 2006;106(1):112-9.
2005: Andrea Kuendgen; Sabine Knipp; Frank Fox; Corinna Strupp; Barbara Hildebrandt; Christian Steidl; Ulrich Germing; Rainer Haas; Norbert Gattermann
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Annals of hematology 2005;84 Suppl 1():61-6.
2005: Ulrich Germing; Barbara Hildebrandt; Michael Pfeilstöcker; Thomas Nösslinger; Peter Valent; Christa Fonatsch; Michael Lübbert; Detlef Haase; Christian Steidl; Otto Krieger; Reinhard Stauder; Aristoteles Giagounidis; Corinna Strupp; Andrea Kündgen; T Mueller; Rainer Haas; Norbert Gattermann; Carlo Aul
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Leukemia 2005;19(12):2223-31.
2005: Ross Levine; Marc Loriaux; Brian J P Huntly; Mignon L Loh; Miroslav Beran; Eric P Stoffregen; Roland Berger; Jennifer J Clark; Stephanie G Willis; Kim T Nguyen; Nikki J Flores; Elihu Estey; Norbert Gattermann; Scott A Armstrong; A Thomas Look; James D Griffin; Olivier A Bernard; Michael C Heinrich; D Gary Gilliland; Brian J Druker; Michael W N Deininger
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Blood 2005;106(10):3377-9.
2005: Ralf Kronenwett; Ulf Butterweck; Ulrich Steidl; Slawomir Kliszewski; Frank Neumann; Simone Bork; Elena Diaz Blanco; Nicole Roes; Thorsten Graef; Benedikt Brors; Roland Eils; Christian Maercker; Guido Kobbe; Norbert Gattermann; Rainer Haas
Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.
Oncogene 2005;24(34):5313-24.
2005: Corinna Strupp; Roland Fenk; Andrea Kündgen; Norbert Gattermann; Rainer Haas; Ulrich Germing
Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Leukemia research 2005;29(8):967-9.
2005: Corinna Strupp; Ulrich Germing; Manuel Aivado; Andrea Kündgen; Roland Fenk; Ali Hünerlitürkoglu; Guido Kobbe; Rainer Haas; Norbert Gattermann
The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
Leukemia & lymphoma 2005;46(7):999-1006.
2005: Sabine Knipp; Barbara Hildebrandt; Jutta Richter; Rainer Haas; Ulrich Germing; Norbert Gattermann
Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7.
Haematologica 2005;90(5):691-3.
2005: Mignon L Loh; Simone Martinelli; Viviana Cordeddu; Melissa G Reynolds; Shashaank Vattikuti; Connie M Lee; Michael Wulfert; Ulrich Germing; Peter Haas; Charlotte Niemeyer; Miloslav E Beran; Sara Strom; Michael Lübbert; Mariella Sorcini; Elihu H Estey; Norbert Gattermann; Marco Tartaglia
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia research 2005;29(4):459-62.
2005: Frank Neumann; N Teutsch; Slawomir Kliszewski; Simone Bork; Ulrich Steidl; Benedikt Brors; N Schimkus; N Roes; Ulrich Germing; Barbara Hildebrandt; Brigitte Royer-Pokora; R Eils; Norbert Gattermann; Rainer Haas; Ralf Kronenwett
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib.
Leukemia 2005;19(3):458-60.
2004: Janpeter Nickel; Eva Neuen-Jacob; Andreas Saleh; Norbert Gattermann; Hans-Peter Hartung; Hubertus Köller
CIDP and isolated osteosclerotic myeloma.
Neurology 2004;63(12):2439.
2004: Norbert Gattermann; M Dadak; Götz Hofhaus; Michael Wulfert; Mark Berneburg; M L Loeffler; H A Simmonds
Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration.
Nucleosides, nucleotides & nucleic acids 2004;23(8-9):1275-9.
2004: Andrea Kuendgen; Corinna Strupp; Manuel Aivado; Alf Bernhardt; Barbara Hildebrandt; Rainer Haas; Ulrich Germing; Norbert Gattermann
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Blood 2004;104(5):1266-9.
2004: Ulrich Germing; Corinna Strupp; Andrea Kündgen; David Bowen; Carlo Aul; Rainer Haas; Norbert Gattermann
No increase in age-specific incidence of myelodysplastic syndromes.
Haematologica 2004;89(8):905-10.
2004: Ulrich Germing; Andrea Kündgen; Norbert Gattermann
Risk assessment in chronic myelomonocytic leukemia (CMML).
Leukemia & lymphoma 2004;45(7):1311-8.
2004: Norbert Gattermann; Michael Wulfert; Bärbel Junge; Ulrich Germing; Rainer Haas; Götz Hofhaus
Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome.
Blood 2004;103(4):1499-502.
2004: Corinna Strupp; Ulrich Germing; A Scherer; Andrea Kündgen; Ulrich Mödder; Norbert Gattermann; Rainer Haas
Thalidomide for the treatment of idiopathic myelofibrosis.
European journal of haematology 2004;72(1):52-7.
2004: Norbert Gattermann
Mitochondrial DNA mutations in the hematopoietic system.
Leukemia 2004;18(1):18-22.
2003: Martin C Müller; Norbert Gattermann; Tanja Lahaye; Michael W N Deininger; A Berndt; Stefan Fruehauf; Andreas Neubauer; Thomas Fischer; Dieter K Hossfeld; Folker Schneller; S W Krause; Christoph Nerl; Herbert G Sayer; Oliver G Ottmann; C Waller; Walter Aulitzky; Philipp le Coutre; Mathias Freund; Kirsten Merx; Peter Paschka; Heiko König; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Leukemia 2003;17(12):2392-400.
2003: E Misgeld; A Wehmeier; O Krömeke; Norbert Gattermann
Primary non-Hodgkin's lymphoma of bone: three cases and a short review of the literature.
Annals of hematology 2003;82(7):440-3.
2003: Corinna Strupp; B Hildebrandt; U Germing; R Haas; Norbert Gattermann
Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome.
Leukemia 2003;17(6):1200-2.
2003: Corinna Strupp; Norbert Gattermann; Aristoteles Giagounidis; Carlo Aul; Barbara Hildebrandt; Rainer Haas; Ulrich Germing
Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
Leukemia research 2003;27(5):397-404.
2003: Frank Neumann; Caroline Herold; Barbara Hildebrandt; Guido Kobbe; Manuel Aivado; Astrid Rong; Maren Free; Renate Rössig; Roland Fenk; Peter Schneider; Norbert Gattermann; Brigitte Royer-Pokora; Rainer Haas; Ralf Kronenwett
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
European journal of haematology 2003;70(1):1-10.
2003: Götz Hofhaus; Mark Berneburg; Michael Wulfert; Norbert Gattermann
Live now--pay by ageing: high performance mitochondrial activity in youth and its age-related side effects.
Experimental physiology 2003;88(1):167-74.
2002: Norbert Gattermann; Michael Wulfert; Götz Hofhaus
How frequent is mutation in the mitochondrial cytochrome c oxidase gene in patients with myelodysplastic syndromes?
British journal of haematology 2002;119(4):1139; author reply 1139-40.
2002: Guido Kobbe; Peter Schneider; Manuel Aivado; Fabian Zohren; Dominique Schubert; Roland Fenk; Frank Neumann; Ralf Kronenwett; Hildegard Pape; Astrid Rong; Brigitte Royer-Pokora; Barbara Hildebrandt; Ulrich Germing; Norbert Gattermann; Axel Heyll; Rainer Haas
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.
Experimental hematology 2002;30(11):1346-53.
2002: Axel Scherer; Hans-Jörg Wittsack; Corinna Strupp; Norbert Gattermann; Rainer Haas; Ulrich Mödder
Vertebral fractures in multiple myeloma: first results of assessment of fracture risk using dynamic contrast-enhanced magnetic resonance imaging.
Annals of hematology 2002;81(9):517-21.
2002: Axel Scherer; Hans-Jörg Wittsack; Volkher Engelbrecht; Corinna Strupp; Ludger W Poll; Reinhart Willers; P Schneider; Norbert Gattermann; Rainer Haas; Ulrich Mödder
[Does dynamic contrast-enhanced MRI enable recognition of development of vertebral fractures in multiple myeloma?].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2002;174(8):984-90.
2002: Ulrich Germing; Corinna Strupp; Manuel Aivado; Norbert Gattermann
New prognostic parameters for chronic myelomonocytic leukemia.
Blood 2002;100(2):731-2; author reply 732-3.
2002: Manuel Aivado; Astrid Rong; M Stadler; Ulrich Germing; Aristoteles Giagounidis; Corinna Strupp; J Novotny; K M Josten; Guido Kobbe; Barbara Hildebrandt; Norbert Gattermann; Carlo Aul; Rainer Haas; Arnold Ganser
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells.
European journal of haematology 2002;68(4):210-6.
2002: Ulrich Steidl; Ralf Kronenwett; Ulrich-Peter Rohr; Roland Fenk; Slawomir Kliszewski; Christian Maercker; Peter Neubert; Manuel Aivado; Judith Koch; Olga Modlich; Hans Bojar; Norbert Gattermann; Rainer Haas
Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells.
Blood 2002;99(6):2037-44.
2002: A Scherer; Corinna Strupp; Hans-Jörg Wittsack; Volkher Engelbrecht; Reinhart Willers; Ulrich Germing; Norbert Gattermann; Rainer Haas; Ulrich Mödder
[Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy].
Der Radiologe 2002;42(3):222-30.
2002: A Scherer; Corinna Strupp; Hans-Jörg Wittsack; Volkher Engelbrecht; Ludger W Poll; U Reinwand; Reinhart Willers; U Germing; Norbert Gattermann; R Haas; U Mödder
[Dynamic MRI of the lumbar spine for the evaluation of microcirculation during anti-angiogenetic therapy in patients with myelodysplastic syndromes].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2002;174(2):164-9.
2002: Peter L Greenberg; Neal S Young; Norbert Gattermann
Myelodysplastic syndromes.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():136-61.
2002: Corinna Strupp; Manuel Aivado; Ulrich Germing; Norbert Gattermann; Rainer Haas
Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports.
Leukemia & lymphoma 2002;43(1):133-7.
2002: Corinna Strupp; Ulrich Germing; Manuel Aivado; E Misgeld; Rainer Haas; Norbert Gattermann
Thalidomide for the treatment of patients with myelodysplastic syndromes.
Leukemia 2002;16(1):1-6.
2001: Ulrich Germing; Norbert Gattermann
Refractory anemia with excess of blasts in transformation: a dying category?
Leukemia research 2001;25(12):1095-6.
2001: E Misgeld; Norbert Gattermann; A Wehmeier; C Weiland; U Peters; E Kohne
Hemoglobinopathy York [beta146 (HC3) His==>Pro]: first report of a family history.
Annals of hematology 2001;80(6):365-7.
2001: E Misgeld; Ulrich Germing; Carlo Aul; Norbert Gattermann
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma.
Leukemia research 2001;25(1):95-98.
2000: Corinna Strupp; Ulrich Germing; I Trommer; Norbert Gattermann; Carlo Aul
Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature.
Leukemia research 2000;24(12):1059-62.
2000: Ulrich Germing; Norbert Gattermann; Corinna Strupp; Manuel Aivado; Carlo Aul
Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.
Leukemia research 2000;24(12):983-92.
2000: Manuel Aivado; Astrid Rong; Ulrich Germing; Norbert Gattermann; Guido Kobbe; C Rieth; Rainer Haas; Carlo Aul
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.
British journal of haematology 2000;110(4):884-6.
2000: Ulrich Germing; Norbert Gattermann; Manuel Aivado; Barbara Hildebrandt; Carlo Aul
Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction.
British journal of haematology 2000;108(4):724-8.
2000: Norbert Gattermann
From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes.
Leukemia research 2000;24(2):141-51.
1999: Götz Hofhaus; Norbert Gattermann
Mitochondria harbouring mutant mtDNA--a cuckoo in the nest?
Biological chemistry 1999;380(7-8):871-7.
1999: Carlo Aul; Ulrich Germing; H Minning; Guido Kobbe; Norbert Gattermann; Thomas Südhoff; Gerald Meckenstock; Dietmar Söhngen; Axel Heyll
[Role of aggressive treatment strategies for myelodysplastic syndromes].
Praxis 1999;88(10):431-8.
1999: Michael P Schön; Julia Reifenberger; S von Schmiedeberg; Mosaad Megahed; K Lang; Norbert Gattermann; Gerald Meckenstock; G Goerz; Thomas Ruzicka
Multiple basal cell carcinomas associated with hairy cell leukaemia.
The British journal of dermatology 1999;140(1):150-3.
1999: Y L Wang; H K Choi; C Aul; Norbert Gattermann; Jürgen J Heinisch
The MERRF mutation of mitochondrial DNA in the bone marrow of a patient with acquired idiopathic sideroblastic anemia.
American journal of hematology 1999;60(1):83-4.
1998: S Bröker; B Meunier; P Rich; Norbert Gattermann; Götz Hofhaus
MtDNA mutations associated with sideroblastic anaemia cause a defect of mitochondrial cytochrome c oxidase.
European journal of biochemistry / FEBS 1998;258(1):132-8.
1998: Götz Hofhaus; Norbert Gattermann; J A Enríquez
Antisense RNA crossing mitochondrial membrane?
Blood 1998;92(8):2994-5.
1998: Ulrich Germing; Norbert Gattermann; H Minning; Axel Heyll; Carlo Aul
Problems in the classification of CMML--dysplastic versus proliferative type.
Leukemia research 1998;22(10):871-8.
1998: Carlo Aul; Ulrich Germing; Norbert Gattermann; H Minning
Increasing incidence of myelodysplastic syndromes: real or fictitious?
Leukemia research 1998;22(1):93-100.
1997: Norbert Gattermann; S Retzlaff; Y L Wang; Götz Hofhaus; Jürgen J Heinisch; Carlo Aul; W Schneider
Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia.
Blood 1997;90(12):4961-72.
1997: Carlo Aul; Norbert Gattermann; Ulrich Germing; Thomas Südhoff; KA Hollmig; Axel Heyll
Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia.
Leukemia research 1997;21(3):249-53.
1997: Carlo Aul; H Minning; Thomas Südhoff; Norbert Gattermann; Axel Heyll
Recurrent reversible nephrotic syndrome during therapy with recombinant interferon alpha.
American journal of hematology 1997;54(1):91.
1996: Carlo Aul; Ulrich Germing; Norbert Gattermann; Dietmar Söhngen; Axel Heyll
[The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome].
Deutsche medizinische Wochenschrift (1946) 1996;121(37):1113-8.
1996: Norbert Gattermann; S Retzlaff; Y L Wang; Mark Berneburg; Jürgen J Heinisch; Meinhard Wlaschek; Carlo Aul; W Schneider
A heteroplasmic point mutation of mitochondrial tRNALeu(CUN) in non-lymphoid haemopoietic cell lineages from a patient with acquired idiopathic sideroblastic anaemia.
British journal of haematology 1996;93(4):845-55.
1996: Norbert Gattermann; Carlo Aul
[Diagnosis and therapy strategy in myelodysplastic syndromes].
Praxis 1996;85(3):39-44.
1995: Norbert Gattermann; Mark Berneburg; Jürgen J Heinisch; Carlo Aul; W Schneider
Detection of the ageing-associated 5-Kb common deletion of mitochondrial DNA in blood and bone marrow of hematologically normal adults. Absence of the deletion in clonal bone marrow disorders.
Leukemia 1995;9(10):1704-10.
1995: Carlo Aul; Norbert Gattermann; W Schneider
Epidemiological and etiological aspects of myelodysplastic syndromes.
Leukemia & lymphoma 1995;16(3-4):247-62.
1994: Carlo Aul; Norbert Gattermann; Ulrich Germing; V Runde; Axel Heyll; W Schneider
Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score.
Leukemia 1994;8(11):1906-13.
1994: W Schneider; Norbert Gattermann
Megakaryocytes: origin of bleeding and thrombotic disorders.
European journal of clinical investigation 1994;24 Suppl 1():16-20.
1994: Carlo Aul; Norbert Gattermann; Ulrich Germing; M Winkelmann; Axel Heyll; V Runde; W Schneider
Serum deoxythymidine kinase in myelodysplastic syndromes.
Cancer 1994;73(2):322-7.
1993: Norbert Gattermann; Carlo Aul; W Schneider
Is acquired idiopathic sideroblastic anemia (AISA) a disorder of mitochondrial DNA?
Leukemia 1993;7(12):2069-76.
1993: Carlo Aul; V Runde; Norbert Gattermann
All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study.
Blood 1993;82(10):2967-74.
1992: Carlo Aul; Norbert Gattermann; W Schneider
Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.
British journal of haematology 1992;82(2):358-67.
1992: Carlo Aul; Norbert Gattermann; Ulrich Germing; V Runde; Axel Heyll
[Myelodysplastic syndromes. The epidemiological and etiological aspects].
Deutsche medizinische Wochenschrift (1946) 1992;117(33):1223-31.
1992: Carlo Aul; Norbert Gattermann; W Schneider
Comparison of in vitro growth characteristics of blast cell progenitors (CFU-L) in patients with myelodysplastic syndromes and acute myeloid leukemia.
Blood 1992;80(3):625-33.
1992: Carlo Aul; Norbert Gattermann; Axel Heyll; Ulrich Germing; G Derigs; W Schneider
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Leukemia 1992;6(1):52-9.
1992: Carlo Aul; Norbert Gattermann
The role of low-dose chemotherapy in myelodysplastic syndromes.
Leukemia research 1992;16(3):207-15.
1991: Norbert Gattermann; W Schneider
[The leukostasis syndrome].
Deutsche medizinische Wochenschrift (1946) 1991;116(37):1399-404.
1991: Gerald Meckenstock; Norbert Gattermann; W Schneider; M Siebler
[The leukostasis syndrome with a cerebral infarct in rapidly progressing chronic lymphatic leukemia].
Deutsche medizinische Wochenschrift (1946) 1991;116(37):1388-92.
1991: Carlo Aul; Norbert Gattermann; W Schneider
Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b.
European journal of haematology 1991;46(1):11-6.
1990: M Thomas; Norbert Gattermann; W Schneider
Refractory and relapsing Hodgkin's disease: role of high-dose chemotherapy with bone marrow transplantation.
Klinische Wochenschrift 1990;68(11):539-44.
1990: Norbert Gattermann; Carlo Aul; W Schneider
Risk of leukemic transformation in two types of acquired idiopathic sideroblastic anemia.
Haematology and blood transfusion 1990;33():374-81.
1990: Norbert Gattermann; Carlo Aul; W Schneider
Two types of acquired idiopathic sideroblastic anaemia (AISA)
British journal of haematology 1990;74(1):45-52.
1987: C Aul; Axel Heyll; Norbert Gattermann; W Schneider
[Treatment of myelodysplastic syndromes].
Deutsche medizinische Wochenschrift (1946) 1987;112(8):309-13.